Specifically, the increased CSF T‐tau and P‐tau levels in preclinical AD, in the absence of increased 18F‐AV‐1451 retention, are compatible with an increased release of tau from neurons in early stages of AD, before overt tau pathology has accumulated. Here, MAPT is linked to Alzheimer disease.